RA Capital Healthcare Fund Sells $253K in Werewolf Therapeutics Stock
HOWL is trading near its 52-week low of $0.355 (8.9% above the low).
Summary
RA Capital Healthcare Fund, a 10% owner, sold $253,569 worth of Werewolf Therapeutics common stock, continuing a trend of institutional selling amidst the company's financial challenges.
Key Events · Ownership and Investor Activity · HOWL
-
Institutional Shareholder Sale
RA Capital Healthcare Fund, a 10% owner, sold 678,226 shares of common stock for a total value of $253,569 in open market transactions between June 9 and June 11, 2026.
-
Ongoing Institutional Distribution
This sale contributes to a broader pattern of institutional investors reducing their holdings in Werewolf Therapeutics, following multiple Form 144 and 13D/A filings from other funds in recent months.
-
Context of Financial Distress
The sale occurs while Werewolf Therapeutics has disclosed substantial doubt about its ability to continue as a going concern and is actively exploring strategic alternatives, including a potential sale or merger.
Analysis · HOWL · Life Sciences
This Form 4 reports a significant open market sale by RA Capital Healthcare Fund, a major institutional investor. The sale of over $253,000 in shares, representing a notable portion of the company's market value, adds to the ongoing pattern of institutional distribution. This comes as Werewolf Therapeutics faces substantial doubt about its ability to continue as a going concern and is actively exploring strategic alternatives, making any large insider sale a negative signal for investor confidence.
At the time of this filing, HOWL was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $0.36 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.